The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease

BACKGROUND: Sodium–glucose cotransporter 2 (SGLT2) inhibitors are an antihyperglycemic drug with diuretic action. We recently reported that the SGLT2 inhibitor dapagliflozin ameliorates extracellular volume expansion with a mild increase in urine volume. However, the impact of the pretreatment extra...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohara, Ken, Masuda, Takahiro, Morinari, Masato, Okada, Mari, Miki, Atsushi, Nakagawa, Saki, Murakami, Takuya, Oka, Kentaro, Asakura, Maki, Miyazawa, Yasuharu, Maeshima, Akito, Akimoto, Tetsu, Saito, Osamu, Nagata, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195732/
https://www.ncbi.nlm.nih.gov/pubmed/32377235
http://dx.doi.org/10.1186/s13098-020-00545-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195732/
https://www.ncbi.nlm.nih.gov/pubmed/32377235
http://dx.doi.org/10.1186/s13098-020-00545-z

Ejemplares similares